Clinical efficacy of mucoactive therapy with 7% hypertonic saline in patients with acute bronchitis

Abstract

Introduction. Respiratory viruses are the overwhelming etiological agents of acute bronchitis in adults. However, the routine management of such patients often includes the prescription of antibiotics. The primary treatment for acute bronchitis is the administration of mucoactive agents to liquefy and improve sputum flow.The aim is to investigate the efficacy and safety of 7% hypertonic solution in patients with acute bronchitis.Materials and methods. A total of 50 patients were enrolled, of whom 25 participants received Ingasalin® forte (7% hypertonic solution) and 25 patients formed a second control group in which participants received other drugs as mucoactive therapy (routine clinical practice).Results. Severity of productive cough in Group 1 patients equaled 2,24 ± 0,4 points, in Group 2 – 2,4 ± 0,5 points. On the 4th day there was a significant reduction in the severity of both daytime and nighttime cough in the vast majority of patients. At the same time, severity of daytime cough on the 4th day of treatment in Group 1 was equal to 1,36 ± 0,5, and in Group 2 – to 1,7 ± 0,5. During the same period, the number of AB patients with a significant reduction in cough severity in group 1 was 16 (64%), while in group 2–8 (32%).Conclusion. Thus, the use of 7% hypertonic solution was accompanied by a good effect in the form of a pronounced cough regression in patients with AB.